ADC THERAPEUTICS SA (ADCT) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ADCT - CH0499880968 - Common Stock
ADCT Key Statistics, Chart & Performance
The current stock price of ADCT is 3.97 USD. In the past year, price increased by 102.55%.
ADCT Latest News, Press Relases and Analysis
ADCT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.67 | 395.31B | ||
| AMGN | AMGEN INC | 14.94 | 175.94B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 147.37B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.21 | 115.43B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.58 | 78.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767 | 51.68B | ||
| INSM | INSMED INC | N/A | 42.80B | ||
| NTRA | NATERA INC | N/A | 31.38B | ||
| BIIB | BIOGEN INC | 10.24 | 25.16B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.95 | 21.53B | ||
| INCY | INCYTE CORP | 15.11 | 19.05B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About ADCT
Company Profile
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Company Info
ADC THERAPEUTICS SA
Biopole, route de la Corniche 3B
Epalinges VAUD 1066 CH
CEO: Christopher Martin
Employees: 263
Phone: 41216530200
ADC THERAPEUTICS SA / ADCT FAQ
Can you describe the business of ADC THERAPEUTICS SA?
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
What is the current price of ADCT stock?
The current stock price of ADCT is 3.97 USD. The price decreased by -5.7% in the last trading session.
What is the dividend status of ADC THERAPEUTICS SA?
ADCT does not pay a dividend.
How is the ChartMill rating for ADC THERAPEUTICS SA?
ADCT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of ADC THERAPEUTICS SA (ADCT) based on its PE ratio?
ADC THERAPEUTICS SA (ADCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.33).
Can you provide the market cap for ADC THERAPEUTICS SA?
ADC THERAPEUTICS SA (ADCT) has a market capitalization of 491.80M USD. This makes ADCT a Small Cap stock.
What is the outstanding short interest for ADC THERAPEUTICS SA?
The outstanding short interest for ADC THERAPEUTICS SA (ADCT) is 6% of its float.
ADCT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ADCT. When comparing the yearly performance of all stocks, ADCT is one of the better performing stocks in the market, outperforming 94.42% of all stocks.
ADCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADCT. ADCT may be in some trouble as it scores bad on both profitability and health.
ADCT Financial Highlights
Over the last trailing twelve months ADCT reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS increased by 44.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.61% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ADCT Forecast & Estimates
12 analysts have analysed ADCT and the average price target is 8.16 USD. This implies a price increase of 105.54% is expected in the next year compared to the current price of 3.97.
For the next year, analysts expect an EPS growth of 12.63% and a revenue growth 5.27% for ADCT